Acquisition Adds New, Minimally Invasive Platform for Neurosurgery

PLAINSBORO, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, announced today that it has acquired Rebound Therapeutics, developers of single-use medical devices that enable minimally invasive access, using optics and illumination, for visualization, diagnostic and therapeutic use in neurosurgery. Rebound’s minimally invasive surgical (MIS) technology features integrated optics and illumination capable of interfacing with existing operating room monitors.

“The acquisition of Rebound Therapeutics reflects Integra’s ongoing commitment to developing innovative products to address unmet needs in neurosurgery,” said Dan Reuvers, corporate vice president and president of Integra LifeSciences’ Codman Specialty Surgical division. “Rebound’s MIS technological platform is a natural addition to our portfolio of neurosurgical products and will expand our therapeutic-focused offerings. We are eager to further develop Rebound’s cutting-edge MIS technologies to help surgeons improve the standard of care for neurosurgery patients.”

“Integra has a strong track record of commercializing technologies and working with surgeons to advance surgical care,” said Jeff Valko, chief executive officer, Rebound Therapeutics. “Through its global neurosurgical sales team, we are looking forward to providing both surgeons and patients with greater access to our products.”

Integra LifeSciences does not expect this acquisition to have a material financial impact in 2019.

About Integra

Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas™, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru™.  For the latest news and information about Integra and its brands, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2018 and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.

Investor Relations Contacts:
Sravan Emany
Senior Vice President, Strategy, Treasury & Investor Relations
(609) 936-2488
sravan.emany@integralife.com 

Michael Beaulieu
Director, Investor Relations
(609) 750-2827
michael.beaulieu@integralife.com 

Media Contact:
Laurene Isip
Senior Director, Global Corporate Communications
(609) 750-7984
laurene.isip@integralife.com